Facial resurfacing with coblation technology

Stephen M. Weber, Brian W. Downs, Mario B.J. Ferraz, Tom D. Wang, Ted A. Cook

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Objective: To describe our experience with coblation technology for facial resurfacing Methods: Retrospective chart review of all patients treated with coblation at our institution Results: Twenty-four patients (22 female) underwent a total of 29 coblation procedures for aging face (n = 21) or acne scarring (n = 3). The perioral region was the most frequently treated aesthetic subunit (n = 14), followed by the lower eyelid (n = 7). Five patients underwent full-face coblation. Three patients underwent a second coblation procedure for aging face while a single patient with severe acne scarring underwent 3 procedures. Repeat coblation was delayed at least 5 months (mean, 9 months). Seventeen coblation procedures (59%) were performed concurrently with procedures including, but not limited to, injection treatment, rhinoplasty, blepharoplasty, or combined face/ necklift; no adverse events occurred. Seven procedures, including a fufl-face coblation, were performed in the office under local anesthesia and oral sedation without any adverse events. Mean follow-up was 6 months (range, 1 week to 24 months). No complications were observed. Al patients were satisfied with the results after their final coblation treatment. Conclusions: Facial coblation is a safe and effective treatment modality for facial resurfacing.

Original languageEnglish (US)
Article number155
JournalMedGenMed Medscape General Medicine
Volume10
Issue number7
StatePublished - Aug 18 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Facial resurfacing with coblation technology'. Together they form a unique fingerprint.

  • Cite this

    Weber, S. M., Downs, B. W., Ferraz, M. B. J., Wang, T. D., & Cook, T. A. (2008). Facial resurfacing with coblation technology. MedGenMed Medscape General Medicine, 10(7), [155].